about
Human cytomegalovirus and transplantation: drug development and regulatory issuesImmune response to HHV-6 and implications for immunotherapyCytomegalovirus antivirals and development of improved animal modelsDisruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancerCurrent and potential treatments for ubiquitous but neglected herpesvirus infectionsCMV-Specific CD8 T Cell Differentiation and Localization: Implications for Adoptive TherapiesA Luciferase Gene Driven by an Alphaherpesviral Promoter Also Responds to Immediate Early Antigens of the Betaherpesvirus HCMV, Allowing Comparative Analyses of Different Human Herpesviruses in One Reporter Cell LineEstablishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay.Effect of ganciclovir for the treatment of severe cytomegalovirus-associated pneumonia in children without a specific immunocompromised stateAn artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia.Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers.Optimal management of cytomegalovirus retinitis in patients with AIDS.An epistatic relationship between the viral protein kinase UL97 and the UL133-UL138 latency locus during the human cytomegalovirus lytic cycle.Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.Prevention of maternal cytomegalovirus infection: current status and future prospects.A Hsp40 chaperone protein interacts with and modulates the cellular distribution of the primase protein of human cytomegalovirus.Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.The oncomodulatory role of human cytomegalovirus in colorectal cancer: implications for clinical trials.Human cytomegalovirus UL97 kinase and nonkinase functions mediate viral cytoplasmic secondary envelopment.Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era.Anti-cytomegalovirus activity of the anthraquinone atanyl blue PRL.Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89.Impaired functionality of antiviral T cells in G-CSF mobilized stem cell donors: implications for the selection of CTL donor.Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges.SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.Human cytomegalovirus primase UL70 specifically interacts with cellular factor Snapin.Uptake and bioconversion of stereoisomeric dipeptide prodrugs of ganciclovir by nanoparticulate carriers in corneal epithelial cells.Progress in the development of new therapies for herpesvirus infectionsNovel heparan sulfate-binding peptides for blocking herpesvirus entry.Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?Non-axial view of the varicella-zoster virus portal protein reveals conserved crown, wing and clip architecture.Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections.Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo.Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.Cytomegalovirus in hematopoietic stem cell transplant recipientsThe Varicella-zoster virus ORF54 gene product encodes the capsid portal protein, pORF54.Recovery from a possible cytomegalovirus meningoencephalitis-induced apparent brain stem death in an immunocompetent man: a case reportExperimental and computational studies on the effects of valganciclovir as an antiviral drug on calf thymus DNA.A model of human cytomegalovirus infection in severe combined immunodeficient mice.
P2860
Q26700020-8713C73F-ED35-4E28-A4A7-06127F598502Q26827409-A9E44A9B-6713-4163-BBAF-0D48381E8993Q27000998-B2479F93-6BCA-4261-81A2-4D34C7064CAFQ27020978-85373126-DC83-4D25-A37D-BACEE025F9E8Q27023452-B0F827E1-6009-4ED0-8978-32FC4B92C8FEQ28073770-CBB5BB99-9E91-4809-BB62-83D124DECA81Q28468422-D0CF8FA8-62ED-4D96-89F3-384C736C1E61Q33331830-5822B092-762C-4CBB-BDEA-F1A78A2BCA47Q33588381-C0C98499-B110-4D3F-96B2-24BC5B52FAA0Q33678775-ECDDF626-CFEC-4F68-BC18-BB380165A06FQ33815957-CB6ECF55-8E02-4CC7-BB20-3DD802A9AA61Q33819834-3BD84DEB-B10A-4C0B-B8AF-B1978699C1B5Q33887700-16CAEBE8-D178-42D9-BA23-59C723CB7E6BQ34027421-9C7DBED9-C2D2-42A1-A84B-BA3AD33E7613Q34272089-D5CC0C60-D40D-4039-ADC1-044055415F40Q34468973-C4505873-908B-4C14-8A0E-141ABBC64FDAQ34483696-6F6CABB3-0990-4B1D-AC14-214F00F16CE9Q34521746-58E78FF2-BDAB-479D-AE58-E9D260BDB55BQ34742654-68417F21-A160-4382-92E6-E4F87E547EBFQ34750093-44B28F82-FCC3-4B00-B0CB-66A56E1A1054Q34902453-A556C582-660D-486E-A8F0-8EA9A0AE9AFFQ34922240-87DE9034-B886-4069-8E5D-E8CB051F9354Q35063668-A042B40D-E026-40D5-AB32-5657DCC0F37DQ35086196-0F3CCDE7-61F1-4B8D-BC06-C51EE7379B21Q35226610-BC434D1F-3C84-4BD5-B2A9-087756774E60Q35270303-33B4A45C-31D5-4426-864A-609EF47BFF28Q35531256-1598F2E8-0598-4812-8647-1541B2066DA2Q35578510-BE558F98-3160-4888-929B-7256DD163E77Q35590695-F711A2B7-9593-4803-BFAF-D325EEDDE444Q35636214-C5FE52A9-6B39-454D-9639-264726266A43Q35692301-23FC7096-A24B-4C8C-8185-E1A20E28C085Q35770254-9570B954-04CD-47A4-B562-723D5FBF2878Q35836837-2CCA013E-C502-49A6-9055-12E8E88E6196Q35845907-E2570E86-F46A-4E34-BD04-0F06986FE2A0Q35859879-3C1467EF-57CA-45F8-8F39-60CF75F0C367Q35922928-BAFE4886-60A6-41E7-AA87-2DE0CC1E6CEBQ35992020-A3EB68D6-7ED3-47A8-8937-F2C7C09C4ED9Q36114878-EFDEC2F5-59EA-4FA6-92D3-F2B74053E1F4Q36167461-4D31E555-CEC7-455B-A2C7-B6B573C71E7DQ36177655-51BDA9A1-3DA8-48C7-A044-9629B46AEDE6
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Antiviral drugs for cytomegalovirus diseases.
@ast
Antiviral drugs for cytomegalovirus diseases.
@en
type
label
Antiviral drugs for cytomegalovirus diseases.
@ast
Antiviral drugs for cytomegalovirus diseases.
@en
prefLabel
Antiviral drugs for cytomegalovirus diseases.
@ast
Antiviral drugs for cytomegalovirus diseases.
@en
P1433
P1476
Antiviral drugs for cytomegalovirus diseases.
@en
P2093
Karen K Biron
P304
P356
10.1016/J.ANTIVIRAL.2006.05.002
P577
2006-05-23T00:00:00Z